8-K: Mereo BioPharma Reports 2025 Results, Setrusumab Misses Primary Endpoints

Mereo BioPharma announced its full year 2025 financial results, highlighting setrusumab's failure to meet primary endpoints in Phase 3 OI studies despite positive secondary outcomes, and an extended cash runway into mid-2027.

Summary

• Full year 2025 net loss was $41.9 million, an improvement from $43.3 million in 2024.
• Cash and cash equivalents stood at $41.0 million as of December 31, 2025, down from $69.8 million in 2024.
• The company expects its cash runway to extend into mid-2027, attributed to cost reductions and delays in setrusumab manufacturing and pre-commercial activities.
• Phase 3 Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta (OI) did not achieve statistical significance for primary endpoints (reduction in annualized clinical fracture rate).
• Setrusumab studies did achieve high statistical significance for the key secondary endpoint of improvement in bone mineral density.
• Further analyses of setrusumab data, including patient subgroups, are ongoing for regulatory agency interactions.
• Site feasibility work for the global Phase 3 pivotal study of alvelestat in AATD-LD has been completed, with active partnering discussions underway.
• shibio, Inc., Mereo's partner for vantictumab, plans to initiate a Phase 2 study in autosomal dominant osteopetrosis Type 2 (ADO2) in the second half of 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative update. The failure of setrusumab's primary endpoints is a significant clinical setback, partially offset by an extended cash runway and progress in other pipeline assets.

Positives

• Net loss improved to $41.9 million in 2025 from $43.3 million in 2024.
• Cash runway extended into mid-2027 due to cost reductions and delayed investments.
• Setrusumab achieved high statistical significance in the key secondary endpoint of bone mineral density improvement in Phase 3 studies.
• Setrusumab demonstrated reductions in vertebral fractures and statistically significant improvements in patient-reported outcomes (PROs) in pediatric and teenage patients in the Orbit study.
• R&D expenses decreased by $3.2 million to $17.8 million in 2025.
• General and administrative expenses decreased by $3.4 million to $23.0 million in 2025.
• Benefit from research and development tax credit increased to $1.9 million in 2025 from $1.649 million in 2024.
• Progress in partnering discussions for alvelestat in AATD-LD.
• Partner shibio plans to initiate a Phase 2 trial for vantictumab in ADO2 in H2 2026.

Negatives

• Setrusumab's Phase 3 Orbit and Cosmic studies failed to achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate.
• Cash and cash equivalents decreased to $41.0 million as of December 31, 2025, from $69.8 million as of December 31, 2024.
• A foreign currency translation loss of $6.3 million was incurred in 2025.

Risks

• Uncertainties inherent in the clinical development process.
• Reliance on third parties to conduct and provide funding for clinical trials.
• Sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all.
• Uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials.
• Dependence on enrollment of patients in clinical trials.
• Potentially smaller than anticipated market opportunities for product candidates.
• Dependence on key executives.
• Ability to maintain compliance with Nasdaq continued listing requirements.

Future Outlook

The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into mid-2027, enabling the potential delivery of several key milestones during 2026. This guidance excludes potential upfront payments from an alvelestat partnership or business development activities for non-core programs. Further analyses of setrusumab data are ongoing for planned interactions with regulatory agencies, and partnering discussions for alvelestat are advancing. shibio plans to initiate a Phase 2 study for vantictumab in the second half of 2026.

Management Comments

• "We believe that these data [from Orbit and Cosmic studies], which include pre-specified sub-groups and ad hoc analyses, may provide the basis for engagement with the regulatory agencies." Denise Scots-Knight, CEO.
• "There are no FDA or EMA therapies approved specifically for OI and although bisphosphonates are used to improved bone mineral density, it remains a high unmet need." Denise Scots-Knight, CEO.
• "Setrusumab has demonstrated statistically significant improvements in bone mineral density as well as compelling reductions in vertebral fractures and statistically significant improvements in PROs of disease pain and daily activity in pediatric and teenage patients." Denise Scots-Knight, CEO.
• "We look forward to providing updates on these efforts as we progress with next steps." Denise Scots-Knight, CEO.
• "Alongside this, our partnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts and our partner shibio has indicated that it plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of this year." Denise Scots-Knight, CEO.
• "Following our cost reductions and delays to investment in manufacturing and pre-commercial activities for setrusumab, our revised financial runway into mid-2027 enables us to potentially deliver on several key milestones during 2026." Denise Scots-Knight, CEO.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in rare diseases, faces significant challenges in clinical trial success. While setrusumab's failure to meet primary endpoints is a setback, the positive secondary endpoint data and PRO improvements highlight the complexity of drug development for conditions like osteogenesis imperfecta, where unmet needs remain high. The strategic out-licensing of vantictumab and ongoing partnering efforts for alvelestat reflect a common industry approach to de-risk development and leverage external funding for pipeline assets, especially for smaller clinical-stage companies.

Comparison to Industry Standards

• The failure of setrusumab to meet primary endpoints in Phase 3 studies for OI is a significant event, as successful primary endpoint achievement is a standard for regulatory approval, similar to challenges faced by other rare disease drug developers like BioMarin Pharmaceutical Inc. with vosoritide for achondroplasia, which ultimately succeeded but highlighted the rigorous nature of trials.
• The statistically significant improvement in bone mineral density and PROs for setrusumab, despite missing the primary fracture endpoint, suggests a partial clinical benefit, reminiscent of situations where drugs like Evenity (romosozumab) for osteoporosis showed strong bone density gains but required careful assessment of fracture reduction.
• The company's strategy to pursue a single Phase 3 trial for alvelestat in AATD-LD, with different primary endpoints for U.S. (SGRQ Total Score) and European (lung density by CT scan) approvals, is a tailored approach to meet specific regulatory requirements, a strategy also employed by companies like Vertex Pharmaceuticals in cystic fibrosis, adapting trial designs for global markets.
• The out-licensing of vantictumab to shibio, Inc. for ADO2, with shibio funding global development, aligns with industry trends where smaller biotechs partner with larger entities or specialized firms to advance programs, as seen with numerous oncology or rare disease assets.

Stakeholder Impact

• Shareholders: Potential negative impact due to the failure of setrusumab's primary endpoints, which could affect future revenue and stock valuation. The extended cash runway provides some stability.
• Patients (OI): Continued high unmet need for an approved therapy, as setrusumab's path to market is now more uncertain despite some positive data.
• Employees: Cost reductions mentioned could imply workforce adjustments, though not explicitly stated.
• Partners (Ultragenyx, shibio, ReproNovo, Feng Biosciences): Continued collaboration on existing agreements, but the setrusumab outcome may impact future milestone payments for Ultragenyx.

Next Steps

• Further analyses of setrusumab data, including patient subgroups, ahead of planned interactions with regulatory agencies.
• Continue active discussions with potential partners for the Phase 3 development and commercialization of alvelestat.
• Initiation of a Phase 2 study for vantictumab in ADO2 by shibio in the second half of 2026.
• Deliver on several key milestones during 2026, supported by the extended cash runway.

Key Dates

Recommendation

While the failure of setrusumab's primary endpoints is a significant negative, the company has extended its cash runway into mid-2027 and is actively pursuing partnerships for other pipeline assets like alvelestat and vantictumab. The positive secondary data for setrusumab also leaves a slim possibility for regulatory engagement. Given the mixed bag of news, a 'hold' recommendation is appropriate to observe the outcome of regulatory discussions for setrusumab and progress on partnering efforts for other programs before making a definitive 'buy' or 'sell' decision.

Keywords

Mereo BioPharma, MREO, Biopharmaceutical, Rare Diseases, Osteogenesis Imperfecta, OI, Setrusumab, UX143, Alpha-1 Antitrypsin Deficiency, AATD-LD, Alvelestat, MPH-966, Autosomal Dominant Osteopetrosis Type 2, ADO2, Vantictumab, OMP18R5, Clinical Trials, Phase 3, Financial Results, Cash Runway, R&D, Nasdaq